Patent Application
20200062738
This invention relates to therapeutic agents that can inhibit cancer cell sternness and the uses of these therapeutic agents in the treatment of cancers.
Most tumors contain heterogenous populations of tumor cells. The bulk of a tumor is made up of proliferative, differentiated cancer cells. However, some cancer cells possess properties of stem cells (i.e., sternness). These stem-cell-like cancer cells (referred to as “cancer stem cells” or CSCs) can produce new cancer cells and give rise to persistence of malignancy.
Recently, BMI-1 (B lymphoma Mo-MLV, insertion region 1 homolog) was found to be involved in cancer cell sternness. BMI-1 can regulate P16 and P19, which are cell cycle inhibitor genes. BMI-1 is elevated in several types of cancers, such as hematologic cancers and brain cancers. Reduction of BMI-1 expression levels in tumor cells can result in apoptosis and/or cell senescence and increases susceptibility to cytotoxic agents.
In addition, BMI1 is found to be rapidly recruited to sites of DNA damage. Loss of BMI1 leads to radiation sensitive and impaired repair of DNA double-strand breaks by homologous recombination.
Bmi1 is necessary for efficient self-renewing cell divisions. Bmi-1 plays a role in the maintenance of cancer stem cell populations. Kreso et al. (Nat. Med. 20, 29-36 (2014)) demonstrated that by targeting BMI1, they could eliminate human colon cancer stem cells in mouse xenografts. They further showed that a small-molecule BMI-1 inhibitor blocks tumor growth and metastasis in the absence of systemic toxicity, illustrating the feasibility of targeting self-renewal (i.e., inhibiting cancer stemness) as a new strategy for the treatment of cancers.
U.S. Patent Application Publication Nos. 2015/0315182, 2016/0214978, 2016/0280685, and 2016/0297798 by PTC Therapeutics, Inc. (South Plainfield, N.J.) disclose several inhibitors of BMI-1 and methods to treat cancers mediated by BMI-1.
Another molecule, Myeloid cell leukemia sequence 1 (MCL1) has also been found to confer resistance to chemotherapy by expanding cancer stem cells (CSCs). MCL-1 is a Bcl-2 family member and is an important anti-apoptotic protein in the development of multiple cell types.
Although prior art inhibitors of BMI-1 are known, there is a need for more effective inhibitors of BMI-1/MCL-1 for controlling cancer cell sternness.
Embodiments of the invention relate to compounds that can inhibit BMI-1 and/or MCL-1 and can be used to treat various cancers.
One aspect of the invention relates to compounds having a structure described by formula (I) or pharmaceutically acceptable salts thereof, as inhibitors of BMI-1 and/or MCL-1 are useful in the treatment of tumor and cancer-stem-cell related diseases.
wherein
X and Y are each independently selected from the group consisting of CH2, CH, O, S, N, and NH;
Ar1 and Ar2 are each independently selected from the group consisting of aryl and heteroaryl, wherein the aryl or heteroaryl is each optionally substituted with one or more substituents selected from Ra and Rb;
L is one selected from the group consisting of: (C1-6)alkyl, (C2-6)alkene, CONRa, NRaCO, S(O)nNRa, NRaS(O)n, RaNCONRa, RaNS(O)nNRa, RaNC(S)NRa, C(S)NRa, NRa, piperazine, O, and S;
Ra and Rb are each independently selected from the group consisting of hydrogen, halogen, (C1-6)alkyl, (C1-6)alkoxyl, O—(C1-6)alkyl, S—(C1-6)alkyl, aryl, heteroaryl, N(Rc)(Rd), CORc, CON(Rc)(Rd), NRc—CO—N(Rc)(Rd), O—CO—N(Rc)(Rd), NRc—S(O)n—N(Rc)(Rd), or
Ra and Rb can join together with carbon, nitrogen or sulfur atoms, to which they are attached, to form a ring selected from the group consisting of a cycloalkyl and a heterocycloalkyl;
Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, (C1-6)alkyl, (C1-6)alkoxyl, (C6-19)aryl, heteroaryl, (C3-12)cycloalkyl, or Rc and Rd can join together with carbon, nitrogen or sulfur atoms, to which they are attached, to form a 5-7 membered ring; and
n is 0, 1, or 2.
In accordance with some embodiments of the invention, a compound of the invention comprises a structure having the above described Formula I, wherein X is NH and Y is CH, or wherein X is CH and Y is NH. In any of the above embodiments, Ar1 may be phenyl or pyridyl. In particular embodiments, X is NH and Y is CH. In any of the above embodiments, Ar1 may be phenyl.
One aspect of the invention relates to pharmaceutical compositions for treating cancer growth, recurrence, metastasis, or resistance to therapeutics. A pharmaceutical composition in accordance with one embodiment of the invention comprises an effective amount of any one of the above described compounds having a structure depicted by Formula (I).
In accordance with embodiments of the invention, any cancer that is associated with overexpression of BMI-1 and/or MCL-1 can be prevented or treated with a compound of the invention. In accordance with some embodiments of the invention, the cancer may be a lung cancer.
Other aspects of the invention will become apparent with the following description and examples.
The term “alkyl” means carbon chains without double or triple bonds, and that may be linear and/or branched. An “alkyl” may be further defined by the number of carbons in the group, such as C1-C3 alkyl, C1-C6 alkyl, C1-C12 alkyl, and so on. For example, C1-C6 alkyl is defined as an alkyl group having 1, 2, 3, 4, 5 or 6 carbons. In this description, the number of carbons may be denoted as “C1-C6” or “C1-6.”. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, and the like. Similarly, the term “C0-C4 alkyl” includes alkyls containing 4, 3, 2, 1, or no carbon atoms. An alkyl group with no carbon is a hydrogen, or a direct bond when the alkyl is a bridging moiety.
The term “alkyl” is used broadly to include “alkylenyl,” a bivalent alkyl linking two residues. Examples of bivalent “alkyl” include: —CH2—, —CH2—CH2—, etc.
The term “alkene” or “alkenyl” means a linear and/or branched structure having at least one C—C double bond. An “alkene” may be further defined by the number of carbons, such as C2-C6 alkene, C2-C12 alkene, and so on. A C2-C6 alkene, for example, includes ethylene, propylene, butylenes, and the like. Similarly, “alkenyl” may be used broadly to include bivalent “alkenyl” that links two residues. A C2-C6 alkenyl, for example, includes ethylenyl, propylenyl, butylenyl, and the like.
The term “alkynyl” means a linear and/or branched structure having at least one C—C triple bond. An “alkynyl” group may be further defined by the number of carbons, such as C2-C6 alkynyl, C2-C12 alkynyl, and so on. For example, C2-C6 alkynyl is defined as a group having 2, 3, 4, 5 or 6 carbon in a linear and/or branched arrangement. Similarly, C2-C6 alkynyl includes 2-hexynyl, 2-pentynyl, or the like.
The term “alkoxy” as used herein includes an alkyl group, as defined above, connected to an oxygen atom. The term “alkoxy” also includes alkyl ether groups, where the term “alkyl” is as defined above, and “ether” means two alkyl groups with an oxygen atom between them. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, and n-butoxy.
The term “aryl,” unless specifically stated otherwise, means any stable monocyclic or fused carbon rings of up to 7 members in each ring, wherein at least one ring is aromatic. An “aryl” group may be defined by the number of carbons, such as (C6-12)aryl, (C6-19)aryl, and so on. Example of such aryl groups include phenyl, naphthyl, and tolyl.
The term “aryloxy” means an aryl group as defined above connected through an oxygen atom.
The term “cycloalkyl” means carbocycles containing no heteroatoms, and includes mono-, bi- and tricyclic saturated carbocycles, as well as fused ring systems. Such fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzofused carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems. An “cycloalkyl” group may be defined by the number of carbons, such as (C3-6)cycloalkyl, (C3-12)cycloalkyl, (C3-19)cycloalkyl, and so on. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantanyl, indanyl, indenyl, and fluorenyl.
Similarly, “cycloalkenyl” means carbocycles containing no heteroatoms and at least one nonaromatic C—C double bone. Cycloalkenyl may include mono-, bi- and tricyclic partially saturated carbocycles, as well as benzofused cycloalkenes. An “cycloalkenyl” group may be defined by the number of carbons, such as (C3-6)cycloalkenyl, (C3-12)cycloalkenyl, and (C3-19)cycloalkenyl. Examples of cycloalkenyl include cyclohexenyl and indenyl.
The term “cycloalkyloxy” includes a cycloalkyl group as defined above connected to an oxy connecting atom.
The term “hetero,” unless specifically stated otherwise, includes one or more O, S, and/or N atoms. For example, “heterocycloalkyl” (or heterocyclyl) and “heteroaryl” include ring systems that contain one or more O, S, and/or N atoms in the ring.
The term “heterocycloalkyl” means a clycolalkyl as defined above, in which one or more ring carbons are replaced with hetero atoms, such as O, S, and/or N. Examples of heterocycloalkyl include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and tetrahydrofuranyl. As used herein, “heterocycloalkyl” includes bridged heterocycloalkyls having two or more heterocycloalkyl groups joined via adjacent or non-adjacent atoms.
The term “heteroaryl” as used herein means a monocyclic or multicyclic ring system containing at least one aromatic ring and from one to four heteroatoms selected from N, O and/or S, wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Examples of a heteroaryl may include a stable 5-7 membered monocyclic- or a stable 9-10 membered fused bicyclic heterocyclic ring system, which contains an aromatic ring. The heteroaryl group may be defined by the number of carbons included therein. For example, (C3-19)heteroaryl refers to a heteroaryl group having form 3 to 19 carbons, in addition to the hetero atom(s). Some ring(s) of a multicyclic ring system may be saturated, partially saturated, or unsaturated. A heteroaryl group includes any bicyclic or multicyclic group in which ad heterocyclic ring is fused to an aromatic ring (such as a benzene ring). The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heteroaryl groups include pyridine, pyrimidine, pyrazine, thiophene, oxazole, thiazole, triazole, oxadiazole, pyrrole, 1,2,4-oxadiazole, and 1,3,4-thiadiazole.
The term “heteroaryloxy” describes a heteroaryl group, as defined above, connected through an oxy connecting atom to a connecting site.
The above described ring systems, such as cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, may be further connected to a non-cyclic moiety, such as an alkyl, alkenyl, or alkynyl. In these cases, the cyclic and non-cyclic parts may be separately denoted by the numbers of carbons in each part. For example, (C3-19)heteroaryl(C1-6)alkyl defines a heteroaryl ring having 3-19 carbon atoms attached to an alkyl group having 1-6 carbons. Examples of (C3-19)heteroaryl(C1-6)alkyl include, for example, furylmethyl, thienylethyl, pyrazolylmethyl, and quinoxalinylmethyl.
The term “carbamoyl” may include —NHC(O)O(C1-4)alkyl and —OC(O)NH(C1-4)alkyl.
The term “optionally substituted” includes both substituted and unsubstituted. For example, optionally substituted aryl could represent a pentafluorophenyl or a phenyl ring. Further, the substitution can be made at any or all subparts in a molecule. For example, a substituted aryl(C1-6)alkyl may include one or more substitutions on the aryl group and/or one or more substitutions on the alkyl group.
The term “oxide” of heteroaryl or heterocycloalkyl includes, for example, N-oxides of nitrogen atoms or S-oxides of sulfur atoms. When a group is “absent,” it is “a direct bond.”
Compounds described herein having one or more double bonds may give rise to cis/trans isomers as well as other conformational isomers. The present invention includes all such possible isomers, as well as mixtures thereof.
Unless otherwise indicated by a bond symbol (dash or double dash), the connecting point to a recited group will be on the right-most stated group. That is, for example, a phenylalkyl group is connected to the main structure through the alkyl.
Compounds described herein can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specifics stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be mixtures of stereoisomers.
The compounds of the present invention are useful in various pharmaceutically acceptable salt forms. The term “pharmaceutically acceptable salts” refer to those salt forms which would be apparent to pharmaceutical chemists, e.g., those which are substantially non-toxic and which provide the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion. Conveniently, pharmaceutical compositions may be prepared from the active ingredients in combination with pharmaceutically acceptable carriers.
The pharmaceutically acceptable salts may be prepared from pharmaceutically acceptable non-toxic bases or acids. When a compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganese, potassium, sodium, zinc, and the like salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethanmine, and the like.
When a compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benznesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
Examples of pharmaceutically acceptable salts include mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
Embodiments of the invention relate to compounds that can inhibit BMI-1 and/or MCL-1, which functions to promote cancer cell stemness. Compounds of the invention can be used to treat various cancers, as well as cancer recurrence and metastasis.
In search of BMI-1 and/or MCL-1 inhibitors, inventors of the present invention unexpectedly found an analog of lysergic acid, lisuride, is an effective inhibitor of BMI-1. The structure of lisuride is as shown below:
Preliminary tests confirmed that lisuride inhibited BMI-1 expression (
Therefore, inventors decided to improve this lead compound by breaking its four fused-ring core structure to reduce its Blood-Brain barrier (BBB) penetration ability and to improve its water-solubility. Specifically, the closed ring of the four-ring core of the lisuride was opened to reduce its planarity, and several high polarity groups were introduced to reduce its lipophilicity hydrophobicity. More than 100 derivatives of lisuride were synthesized and tested for anti-BMI-1/MCL-1 efficacy by in vitro (see
Compounds of the invention are not expected to have the ability to cross BBB. Therefore, they are less likely to have impacts on the CNS and are expected to have good BMI-1/MCL-1 inhibitory activities for use in the treatments of cancers. Compounds of the invention having a general structure of Formula I may be synthesized according to the following Scheme I:
As illustrated in Scheme I, the reactions involved are conventional. First, an aromatic bromide (A) is coupled with an aryl boronic acid compound (B) under the catalysis of a palladium catalyst (e.g., PdCl2(dppf), (1,1′-Bis(diphenylphosphino)-ferrocene)-palladium(II) dichloride, which is available commercially, for example from Sigma-Aldrich) in a reaction known as Suzuki Reaction. This coupling produces a product (C), the amino group on which can be further modified with an acyl chloride (D) to form an amide, resulting in compounds of Formula I. Because these reactions are conventional and involve commercially available reagents, one skilled in the art would be able to carry out these reactions without undue experimentation
Representative examples of compounds of Formula I are set forth below in Table 1:
As noted above, the syntheses of compounds of the invention involve conventional organic reactions and use commercially available reagents. One skilled in the art would be able to synthesize these compounds without undue experimentation. The following examples are presented to illustrated certain embodiments of the present invention. These examples are for illustration only and should not be construed as limiting the scope of this invention.
Unless otherwise indicated, 1H NMR data were obtained at 500 MHz and the compounds of this invention demonstrated efficacy in the following assays as having IC50 values of less than 10 μM. The abbreviations used herein are as follows, unless specified otherwise:
7-Bromo-1H-indole (A, 1.0 g, 5.10 mmol), 3-aminobenzeneboronic acid monohydrate (B, 948.5 mg, 6.12 mmol) and K2CO3 (2.82 g, 20.40 mmole) in DMF (16 ml) was degassed and then flushed with N2. Then, PdCl2(dppf) (416.6 mg, 0.510 mmol) was slowly added to the solution. The reaction mixture was heated to 100° C. and stirred for 5.0 hours. The reaction was monitored by TLC, and the reaction mixture was filtered with Celite. The solution was extracted twice with ethyl acetate and the organic layer was washed with brine, dried over MgSO4(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to provide 3-(1H-indol-7-yl)benzenamine (C, 964.7 mg) in 91% yield. LC/MS m/z 208.96. 1H NMR (500 MHz, DMSO-d6) δ 7.37-7.36 (m, 2H), 7.15-7.10 (m, 2H), 7.01 (d, J=7.2 Hz, 1H), 6.90 (s, 1H), 6.80 (d, J=7.6 Hz, 1H), 6.58-6.56 (m, 2H), and 5.12 (s, 2H).
To a solution of 3-(1H-indol-7-yl)benzenamine (C, 137.0 mg, 0.658 mmol) in DMF (2.0 ml) was added K2CO3 (136.4 mg, 0.987 mmol) and 4-Ethylbenzoyl chloride (0.145 ml, 0.987 mmol). The reaction mixture was stirred at 55° C. for 4.0 hours and then quenched with water. The solution was concentrated under reduced pressure, and extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO4(s), and concentrated under reduced pressure to give N-(3-(1H-indol-7-yl)phenyl)-4-ethylbenzamide (44, 122.2 mg) as yellow solids in 55% yield. LC/MS m/z 341.60. 1H NMR (500 MHz, DMSO-d6) δ 10.95 (s, 1H), 10.26 (s, 1H), 8.06 (s, 1H), 7.93-7.92 (d, J=7.6 Hz, 3H), 7.57-7.56 (d, J=7.0 Hz, 1H), 7.51-7.48 (t, J=7.7 Hz, 1H), 7.39-7.36 (m, 3H), 7.3 (s, 1H), 7.13-7.11 (m, 2H), 6.54-6.53 (m, 1H), 2.72-2.67 (m, 2H), and 1.23-1.19 (m, 3H).
Compounds 1-73 listed in Table 1 above were synthesized in a manner similar to that describe in Example 1. Their calculated mass and observed ESI-MS data are provided in Table 2.
The abilities of compounds of the invention to inhibit BMI-1/MCl-1 expressions were assayed with cell cultures. BMI-1 and MCL-1 are overexpressed in many cancers, such as lung cancer cell line H1975. Therefore, cancer cells that overexpress BMI-1/MCL-1 provide a convenient platform for assaying BMI-1/MCL-1 inhibition.
In the following example, the assays use H1975 (ATCC CRL-5908), which is a human lung adenocarcinoma cell line with T790M EGFR mutation and is resistant to the first-generation Tyrosine Kinase Inhibitors, such as Gefitinib. The H1975 cells were cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, in a humidified incubator at 37° C., with 5% CO2.
To test inhibition of BMI-1/MCL-1 expressions, test compounds of the invention each were diluted in culture medium to reach a final concentration of 10 μM, and the cells were incubated with the medium containing these compounds for 6 hours.
After drug treatments, cells were washed twice with PBS, scraped, and resuspended in RIPA buffer containing protease inhibitors (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin). Cell lysate was sonicated for 5-10 min, and centrifuged at 14000 rpm for 20 minutes at 4° C. The supernatant was collected, determined for protein concentrations, and stored at −80° C. before further use.
BMI-1/MCL-1 expression levels may be assessed with western blot analysis. For western blot analysis, all samples were diluted to an equal protein amount (50 μg), and denatured by adding 6× sample buffer (375 mM Tris-HCl, 9% SDS, 50% Glycerol, 0.03% Bromophenol blue) and heated at 95° C. for 5 minutes. The denatured protein samples were then loaded in 10% Tris-Glycine SDS polyacrylamide gel for separating proteins. The power supply for the running condition was set at 80 V for running stacking gel and 100 V for separating gel, respectively. After separation of the proteins, the protein bands were transferred from polyacrylamide gel to a nitrocellulose membrane in a transfer buffer mixture containing 10% 1× transfer stock buffer (250 mM Tris-base, 1.92M Glycine) plus 20% methanol and 70% distilled deionized water. The power supply for the transfer condition was set at 300 mA, and the transfer was carried out on ice for 2.5 hours. The nitrocellulose membranes containing the denatured proteins were blocked with a solution containing 5% skim milk at room temperature for 1 hour.
After blocking, the membranes were washed with TBS containing 0.1% Tween-20 (TBST) for 5 minutes. All membranes were incubated with the primary antibody (BMI-1 antibody, Millipore 05-637, 1:1000) at 4° C. overnight. After washing with TBST (5 min×3), the membranes were incubated with the secondary antibody (HRP-conjugated anti-mouse IgG, Jackson ImmunoReserch LABORATORIES INC., 1:5000) at room temperature for 1 hour. After washing with TBST (5 min×5), the membranes were incubated with chemiluminescence regent for 1 minute and imaged with a Bioluminiscent imaging system (Biospectrum-AC w/Bio Chemi Camera, UVP).
In addition, the membranes were also probed with antibodies against MCL-1 and tubulin. Tubulin functions as an internal control to assess the relative loadings in different lanes on the gel. Myeloid cell leukemia 1 (MCL1) is a pro-survival protein overexpressed in many cancers.
As shown in
The derivatives showing potent anti-BMI-1/MCL-1 effects, such as compounds #43-45 (BI-43-BI-45), were selected for further in vivo anti-tumor test. The in vivo mouse tumor model was established as described below.
After establishment of the tumors in mice, the test compounds were administered at the indicated doses and the tumor sizes were monitored using bioluminescence. The results of tumor sizes (as measured by bioluminescence intensities) were shown in
In this experiment, TARCEVA® (Erlotinib), which is a tyrosine kinase inhibitor and known to inhibit the growths of several cancer cells (e.g., non-small cell lung carcinoma, pancreatic cancer), was used (20 mg/Kg or 20 mpk) as a positive treatment control. Lisuride and BI43-45 are each used at 1 mpk. As shown in
Because compound 44 (BI-44) showed most potent anti-BMI-1 and MCL-1 activities, its efficacy was further examined in 2 orthotopic xenograft animal studies. The mouse cancer models were generated as described above. Orthotopic H1975-Luc model was described as previous study. BI-44 was administrated by IV injection through tail vein, 5 times/7 days, with the doses indicated on the figure. Gefitinib and Afatinib were administrated orally, 5 times/7 days, with the dose of 20 mpk (mg/Kg).
In the first animal model, Mice were orthotopically implanted with H1975-luc cells (106 cells/mouse). On day 0 (defined as 2 days after tumor implantation), mice were started to receive drug treatments for 4 weeks (5 times/week), and the tumor formations were followed by non-invasive imaging on day 14 and 28.
BI-44 was administrated starting 2 days after orthotopic lung tumor implantation according to the administration scheme shown in
The drugs Gefitinib (1st-generation TKI, which does not target EGFR T790M) and Afatinib (2nd-generation TKI, which can target EGFR T790M) were used as negative and positive controls, respectively, because H1975 contains a T790M mutation on EGFR.
A shown in
Quantification of the images showed significantly reduced bioluminescent intensities in mice lungs in both BI-44 (3 mpk) and Afatinib treatment groups (
In the second model, BI-44 was administrated starting 3 weeks after tumor implantation (
The results showed that BI-44 significantly inhibited tumor growth in a dose-dependent manner, based on imaging results of some mice in each group (
In sum, results from these studies show that compounds of the invention can inhibit tumor growth in vivo, presumably by inhibiting BMI-1/MCL-1 functions. These results support that compounds of the invention that can inhibit BMI-1/MCL-1 expression can indeed inhibit tumor growth. Because BMI-1/MCL-1 overexpression is associated with recurrence, metastasis, and resistance of cancers, compounds of the invention can also be used to prevent the recurrence, metastasis, or resistance of cancer cells.
For clarity of illustration, the above examples use BI-44 and lung cancer to demonstrate embodiments of the invention. However, other compounds of the invention have been shown to inhibit BMI-1 and/or MCL-1 expressions. These compounds can also be used to prevent or treat various cancers, including lung cancers and other cancers that are associated with BMI-1 and/or MCL-1 over-expressions.
Advantages of embodiments of the invention may include one or more of the following. Compounds of the invention are novel chemical entities and yet they possess BMI-1/MCL-1 inhibitory activities. Compounds of the invention have chemical structures that are different from known BMI-1 inhibitors (Nature Medicine, 20: 29-36, 2014).
Compounds of the invention can inhibit BMI-1/MCL-1 and can be used to treat cancers. In preliminary studies, compounds of the invention have superior properties to those of Afatinib, an FDA approved drug for treating non-small cell lung adenocarcinoma. Currently, treatments of non-small cell adenocarcinoma are based on tyrosine kinase inhibitors that target EGFR (e.g., Afatinib). Compounds of the invention inhibits a different target, BMI-1. Therefore, compounds of the invention may be used alone or in combination of other therapeutics to treat non-small cell adenocarcinoma. In addition to treating lung cancers, compounds of the invention can also be used to treat squamous cell carcinoma, which currently does not have any effective treatments.
While embodiments of the invention have been illustrated with a limited number of examples, one skilled in the art would appreciate that these examples are for illustration only and that other modifications and variations are possible without departing from the scope of the invention. Therefore, the scope of the protection should only be limited by the attached claims.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2018/030300 | 4/30/2018 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62492284 | Apr 2017 | US |
